Kroll Bond Rating Agency Announces Addition of Stevyn Schutzman
NEW YORK--(BUSINESS WIRE)-- Kroll Bond Rating Agency (KBRA) announced today the appointment of Stevyn Schutzman to the role of Managing Director within KBRA’s Corporates group.
Steve brings with him over 30 years of Corporates experience. He was previously a Managing Director and Portfolio Manager at RBC Capital Markets, LLC. Prior to that, he held several other positions within RBC such as Global Head of Fixed Income & Currencies Strategy & Research where he managed all aspects of Rate, Currency and Credit research as well as Chief Global Macro Strategist. Steve also held positions at Citigroup Global Markets Inc. and Salomon Brothers, Inc. Steve began his career as a Research Consultant at Exxon Research & Engineering. He holds an MS from NYU and a BS from Stony Brook University. Steve has been selected 10 times to Institutional Investor Magazine’s All-America Fixed Income Research team in 2 categories.
“Steve brings a wealth of experience and knowledge to KBRA and we are excited to have him join on our team as we continue to expand into the Corporates market,” said Van Hesser, Senior Managing Director of Corporates at KBRA.
Please visit www.kbra.com for more details.
Follow us on Twitter!@KrollBondRating
About Kroll Bond Rating Agency
KBRA is registered with the U.S. Securities and Exchange Commission as a Nationally Recognized Statistical Rating Organization (NRSRO). In addition, KBRA is recognized by the National Association of Insurance Commissioners (NAIC) as a Credit Rating Provider (CRP).
View source version on businesswire.com: http://www.businesswire.com/news/home/20170119005836/en/
Kroll Bond Rating Agency
Kate Kennedy, 646-731-2348
Managing
Director | Media Relations
[email protected]
Source: Kroll Bond Rating Agency
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Aveanna Healthcare prices secondary offering at $11.75 per share
- WhiteFiber closes $310M convertible notes offering at 5% due 2032
- Silexion Therapeutics faces Nasdaq delisting over equity shortfall
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Citi, RBC Capital, TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share